Showing results (121-130 of 182) with videos related to

Sort By:
Pageof 19
BJU International|March 8, 2008
The morbidity of transperineal template-guided prostate mapping biopsyGregory S Merrick, Walter Taubenslag, Hugo Andreini, et al.
Urology|February 22, 2011
The incidence of transition zone prostate cancer diagnosed by transperineal template-guided mapping biopsy: implications for treatment planningVareel Patel, Gregory S Merrick, Zachariah A Allen, et al.
International Journal of Radiation Oncology, Biology, Physics|April 12, 2011
Serum testosterone kinetics after brachytherapy for clinically localized prostate cancerAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
Brachytherapy|October 29, 2008
Prostate cancer control and survival in Vietnam veterans exposed to Agent OrangeLydia Everly, Gregory S Merrick, Zachariah A Allen, et al.
American Journal of Clinical Oncology|February 7, 2012
Transperineal template-guided mapping biopsy as a staging procedure to select patients best suited for active surveillanceAl V Taira, Gregory S Merrick, Abbey Bennett, et al.
American Journal of Clinical Oncology|December 9, 2008
Effects of the time interval between prostate brachytherapy and postimplant dosimetric evaluation in community practice: analysis of the Pro-Qura databasePeter F Orio, Gregory S Merrick, Peter Grimm, et al.
Brachytherapy|March 13, 2012
Prognostic importance of tobacco use in men receiving definitive prostate brachytherapyAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
International Journal of Radiation Oncology, Biology, Physics|May 2, 2008
Primary causes of death after permanent prostate brachytherapyNathan Bittner, Gregory S Merrick, Robert W Galbreath, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2009
Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapyAl V Taira, Gregory S Merrick, Robert W Galbreath, et al.
Urology|February 24, 2009
Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMBNathan Bittner, Gregory S Merrick, Hugo Andreini, et al.
Pageof 19